WHO is working with Unitaid and other partners to develop implementation science projects to answer outstanding safety issues, implementation challenges, and understand people's preferences for CAB-LA among other HIV prevention choices.
WHO is working with countries, communities and donors including The Global Fund, PEPFAR, and the Bill & Melinda Gates Foundation to support the inclusion of CAB-LA in their programmes and to catalyze implementation science and monitoring of programmes so that CAB-LA can be implemented, safely and effectively, for greatest impact.
The WHO Global PrEP Network will host webinars this year on CAB-LA to provide up-to-date information for countries, communities and implementers and increase awareness.
In April 2022, CAB-LA was added to WHO’s list of Expressions of Interest for evaluation for prequalification, and WHO is working with countries on regulatory approval.
13396
口服暴露前预防药物和长效注射用卡博特韦均十分有效。
Both oralPrEP and CAB-LA are highly effective.
13397
世卫组织将继续对预防方案提供支持。
WHO will continue to support prevention choices.
13398
长效注射用卡博特韦增加了可用的选项，应始终与口服暴露前预防药物一起提供。
CAB-LA increases the options available and should always be offered alongside oral PrEP.
Some people may continue to choose oral PrEP and CAB-LA will likely be preferred by people who find it difficult to take tablets or do not want to do so.
WHO has also released new guidance on Differentiated and simplified PrEP at the AIDS 2022 conference to support easier access, including community delivery.